Host: Leslie P. Lundt, MD

Guest: Jorge Herrera, MD

Since 2001, combination therapy with pegylated interferon with ribavirin is considered the standard of care in hepatitis C treatment. In clinical trials, 50 to 60 percent of patients treated with combination therapy achieved a sustained virologic response, or SVR, meaning the virus is undetectable in their blood. Dr. Jorge Herrera joins host Dr. Leslie Lundt to discuss the state of the art for treatment of Hepatitis C.